Description
The G9P3 monoclonal antibody specifically recognizes mouse EVA1, which is encoded by the Mpzl2 gene. EVA1 is a member of the immunoglobulin-like cell-adhesion molecule (Ig-CAM or IgSF CAM) family, members of which are anchored to the surface of epithelial and endothelial cells via a GPI domain. This class of adhesion molecules interacts intracellularly with cytoskeletal proteins and extracellularly with Ig-CAM family members, by homophilic or heterophilic binding, and with other classes of adhesion molecules such as integrins and cadherins. EVA1 is expressed on and is involved in the structural integrity of epithelia throughout the body, eg mammary glands, liver, inner ear, and the blood-brain barrier. In the thymus, EVA1 is expressed both on thymic epithelial cells (TECs) and on a subset of developing thymocytes, known as DN3. It is a low-affinity mediator of developmental signals between thymocytes and TEC that support the differentiation and survival of both developing thymocytes and the TECs. G9P3 mAb was produced in EVA1 knockout mice immunized with recombinant mouse EVA1 extracellular region, and it recognizes mouse and human EVA1 expressed on transfected cells.
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. BD Horizon Brilliant Violet 421 is covered by one or more of the following US patents: 8,158,444; 8,362,193; 8,575,303; 8,354,239.
9. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
